このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
CytomX Therapeutics バランスシートの健全性
財務の健全性 基準チェック /36
CytomX Therapeuticsの総株主資本は$-31.7M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$184.7Mと$216.4Mです。 CytomX Therapeuticsの EBIT は$10.8Mで、利息カバレッジ比率-1.1です。現金および短期投資は$150.3Mです。
主要情報
0%
負債資本比率
US$0
負債
| インタレスト・カバレッジ・レシオ | -1.1x |
| 現金 | US$150.28m |
| エクイティ | -US$31.68m |
| 負債合計 | US$216.37m |
| 総資産 | US$184.69m |
財務の健全性に関する最新情報
We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely
Nov 17
Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?
Feb 13Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Jun 08Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?
Feb 10We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate
Aug 11Recent updates
The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%
Jun 15We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now
May 09CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling
May 02CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%
Apr 27CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
Apr 25CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%
Mar 05CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Jan 19There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise
Nov 26We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely
Nov 17Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 29Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?
Feb 13Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%
Nov 10CytomX Therapeutics to cut workforce by about 40%
Jul 13CytomX says phase 2 study of breast cancer antibody treatment met main goal
Jul 06Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Jun 08Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?
Feb 10CytomX: Pullbacks Are Opportunities
Dec 14CytomX: Solving A Critical Problem In The High-Value ADC Space
Sep 15We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate
Aug 11Checking In On CytomX Therapeutics
Jun 13Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being
Jun 10CytomX EPS beats by $0.06, misses on revenue
May 06Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 11%
Mar 25財務状況分析
短期負債: CTMXは マイナスの株主資本 を有しており、これは 短期資産 が 短期負債 をカバーしていないことよりも深刻な状況です。
長期負債: CTMXは株主資本がマイナスであり、これは短期資産が 長期負債 をカバーしていないことよりも深刻な状況です。
デット・ツー・エクイティの歴史と分析
負債レベル: CTMXは負債がありません。
負債の削減: CTMXの株主資本はマイナスなので、時間の経過とともに負債が減少したかどうかを確認する必要はありません。
債務返済能力: CTMXには負債がないため、営業キャッシュフロー でカバーする必要はありません。
インタレストカバレッジ: CTMXには負債がないため、利息支払い の負担は問題になりません。